Zobrazeno 1 - 10
of 182
pro vyhledávání: '"Elvira Pelosi"'
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 16, Iss 1 (2024)
Multiple myeloma (MM), characterized by abnormal proliferation of clonal plasma cells, is an incurable hematological malignancy. Various immunotherapy strategies have emerged as an efficacious approach for the treatment of MM, including monoclonal an
Externí odkaz:
https://doaj.org/article/dc319dc577a34aa4bf295fb24119c0dc
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 16, Iss 1 (2024)
Blinatumomab, a CD19-CD3 bispecific T cell engager (BiTE), has two recombinant single-chain variable fragments that temporarily link CD3+ T cells and CD19+ B cells, leading to the T cell-mediated lysis of neoplastic B cells. Improved minimal residual
Externí odkaz:
https://doaj.org/article/880f4b38f3164cb48f22c1876c312b46
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 16, Iss 1 (2024)
Multiple myeloma (MM) is a disorder of the monoclonal plasma cells and is the second most common hematologic malignancy. MM initiation and progression are dependent upon complex genomic abnormalities. The current pathogenic model of MM includes two t
Externí odkaz:
https://doaj.org/article/d55cce9b860d4128a37eb68ba5c25808
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 16, Iss 1 (2024)
The study of monoclonal serum proteins has led to the generation of two major theories: one proposing that individuals who had monoclonal proteins without any symptoms or evidence of end-organ damage have a benign condition; the other one suggesting
Externí odkaz:
https://doaj.org/article/f94bc27a002d489ebcd4f23b80232e3c
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 16, Iss 1 (2024)
The treatment outcomes of patients with chronic lymphocytic leukemia (CLL) have considerably improved with the introduction of targeted therapies based on Bruton kinase inhibitors (BTKIs), venetoclax, and anti-CD20 monoclonal antibodies. However, des
Externí odkaz:
https://doaj.org/article/ed6dee0cb37f4a9db01ec678a57b1ec8
Publikováno v:
Onco, Vol 3, Iss 3, Pp 189-204 (2023)
Non-small-cell lung cancer (NSCLC) is a heterogeneous group of diseases accounting for 80–85% of lung cancers. A molecular subset of NSCLC (1–2.5%) harboring molecular rearrangements of the tyrosine kinase gene ROS1 is defined as ROS1-positive an
Externí odkaz:
https://doaj.org/article/b774edf05d4c4ae9af8c4948d7892342
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 16, Iss 1 (2024)
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes. Thus, six FDA-approved commercial CAR-T cell products that target antigens preferentiall
Externí odkaz:
https://doaj.org/article/b35f4cf3d27344039cf165fcbbd92692
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 16, Iss 1 (2024)
Treatment of refractory and relapsed (R/R) B acute lymphoblastic leukemia (B-ALL) is an unmet medical need in both children and adults. Studies carried out in the last two decades have shown that autologous T cells engineered to express a chimeric an
Externí odkaz:
https://doaj.org/article/6906bae33f5842158b95ccf235573940
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 16, Iss 1 (2024)
Follicular lymphoma is the second most diagnosed lymphoma in Western Europe. Significant advancements have considerably improved the survival of FL patients. However, 10-20% of these patients are refractory to standard treatments, and most of them wi
Externí odkaz:
https://doaj.org/article/e0180e0da7274c5e971c73ca2e54ce9c
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 15, Iss 1 (2023)
Large B-cell lymphomas (LBCLs) are among the most frequent (about 30%) non-Hodgkin’s lymphoma. Despite the aggressive behavior of these lymphomas, more than 60% of patients can be cured with first-line chemoimmunotherapy using the R-CHOP regimen. P
Externí odkaz:
https://doaj.org/article/26df54053eb1407b9889517e98e730cb